---
title: "Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Product information and disease description"
description: "Formulary evidence on Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Product information and disease description. Covers Product description and Place of product in therapy. 73 evidence topics quoted from 60 sources."
canonical: "https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### FDA submission

> “The full submission of the rolling BLA was completed as the Company had previously guided in late December 2024”

Source: [Capricor Therapeutics BLA submission announcement (2025)](https://www.capricor.com/investors/news-events/press-releases/detail/303/capricor-therapeutics-completes-submission-of-biologics)

<a id="topic-2.1.1-2"></a>

##### Complete response letter

> “the BLA does not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data.”

Source: [Capricor Therapeutics July 2025 regulatory update announcement (2025)](https://www.capricor.com/investors/news-events/press-releases/detail/319/capricor-therapeutics-provides-regulatory-update-on)

<a id="topic-2.1.1-3"></a>

##### Regulatory status: Under review; BLA resubmitted February 2026, major amendment submitted August 2026, PDUFA target action date November 22, 2026

> “Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026”
> “In August, the Company submitted two-year OLE data and additional robustness analyses from HOPE-3”
> “The FDA classified the submission as a major amendment, extending the review by three months to November 22, 2026.”

Source: [Capricor Therapeutics third quarter 2026 results announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/359/capricor-therapeutics-reports-third-quarter-2026-financial)

> “The FDA's Center for Biologics Evaluation and Research (CBER) accepted the amendment for review, citing the significant unmet medical need in DMD.”
> “The FDA has classified the submission as a major amendment and extended the PDUFA target action date by three months to allow additional time to review the information.”

Source: [Capricor Therapeutics PDUFA date extension announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/354/capricor-therapeutics-announces-extension-of-pdufa-target)

> “has lifted the previously issued Complete Response Letter and resumed review of its Biologics License Application”
> “The submission has been classified as a Class 2 resubmission”

Source: [Capricor Therapeutics new PDUFA date announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/338/capricor-therapeutics-announces-establishment-of-new-pdufa)

> “We currently have no products approved for commercial sale.”

Source: [Capricor Therapeutics Form 10-K (2026)](https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-029580/capr-20251231x10k.htm)

> “the recent submission of the HOPE-3 clinical study report to the FDA as part of our ongoing BLA review process”

Source: [Capricor Therapeutics MDA 2026 presentation announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/336/capricor-therapeutics-announces-late-breaking-presentation)

> “the Company plans to submit the requested materials to the FDA in February 2026”

Source: [Capricor Therapeutics January 2026 regulatory update announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/335/capricor-therapeutics-provides-regulatory-update-on)

<a id="topic-2.1.1-4"></a>

##### FDA Advisory Committee

> “did not support the effectiveness of Deramiocel for the treatment of cardiomyopathy”
> “(3 for, 9 against, 0 abstain).”
> “The Committee's vote is non-binding.”

Source: [Capricor Therapeutics advisory committee update announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/351/capricor-therapeutics-provides-update-on-fda-advisory)

<a id="topic-2.1.1-5"></a>

##### Anticipated FDA action date

> “New PDUFA target action date of November 22, 2026”

Source: [Capricor Therapeutics PDUFA date extension announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/354/capricor-therapeutics-announces-extension-of-pdufa-target)

<a id="topic-2.1.1-6"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-7"></a>

##### Special FDA designations

> “Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy”

Source: [Capricor Therapeutics (2018)](https://www.capricor.com/investors/news-events/press-releases/detail/119/capricor-receives-fda-regenerative-medicine-advanced)

> “has granted Rare Pediatric Disease Designation to CAP-1002”
> “Orphan Drug Designation previously granted to CAP-1002 by the FDA”

Source: [Capricor Therapeutics (2017)](https://www.capricor.com/investors/news-events/press-releases/detail/135/capricor-receives-rare-pediatric-disease-designation-from)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Capricor Therapeutics

> “Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel”

Source: [Capricor Therapeutics PDUFA date extension announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/354/capricor-therapeutics-announces-extension-of-pdufa-target)

<a id="topic-2.1.2.1-2"></a>

###### Unapproved product name and drug class

> “Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs)”

Source: [Capricor Therapeutics HOPE-3 MDA 2026 data announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/339/capricor-therapeutics-announces-late-breaking-hope-3-data)

<a id="topic-2.1.2.1-3"></a>

###### Cellular composition

> “a population of cardiac-derived stromal cells isolated from qualified donated human hearts”

Source: [Capricor Therapeutics Form 10-K (2026)](https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-029580/capr-20251231x10k.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational cell suspension

> “a human CDC cell suspension”

Source: [Soslow (2026)](https://d1io3yog0oux5.cloudfront.net/_7633595f5f8ea5d280c4a86092c10a63/capricor/files/CAPR_%28ASGCT_2026%29_Soslow.pdf)

<a id="topic-2.1.2.2-2"></a>

###### Deramiocel-specific material safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Product pricing information: allegation in Capricor complaint concerning its distributor

> “It has not established a realistic wholesale price.”

Source: [Capricor Therapeutics complaint (2026)](https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-057221/capr-20260507xex99d2.htm)

<a id="topic-2.1.2.3-2"></a>

###### Marketed-product average sales price and announced wholesale acquisition cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Refined proposed indication

> “a refined proposed indication focused on upper limb function”

Source: [Capricor Therapeutics PDUFA date extension announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/354/capricor-therapeutics-announces-extension-of-pdufa-target)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Proposed mechanism of action

> “CDCs are not stem cells and do not engraft. They exert their anti-fibrotic and anti-inflammatory effects through the release of exosomes.”

Source: [Soslow (2026)](https://d1io3yog0oux5.cloudfront.net/_7633595f5f8ea5d280c4a86092c10a63/capricor/files/CAPR_%28ASGCT_2026%29_Soslow.pdf)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### In vitro potency and antifibrotic activity

> “CDCs in Deramiocel exert quantifiable anti-fibrotic activity in vitro, mediated through exosome and soluble factors in a dose-dependent manner.”

Source: [Li et al. (2025)](https://d1io3yog0oux5.cloudfront.net/_720140307f1b6c7261a7b3c4d8426889/capricor/files/pages/capricor/db/2348/authors/biomedicines-13-02652_%28Capricor%29.pdf)

<a id="topic-2.1.2.6.2-2"></a>

###### Preclinical repeated dosing: mdx mice

> “early and sustained intervention with mCDCs prevents disease progression for up to 1 year in mdx mice.”
> “beneficial effects of hCDC-EVs waned after 6 months”

Source: [Rogers et al. (2025)](https://www.cirm.ca.gov/about-cirm/publications/long-term-preservation-muscle-function-and-structure-repeated-administration-cardiosphere-derived-cells-mdx-mice/)

Additional sources: [Aminzadeh et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29478899/); [Aminzadeh et al. (2026)](https://doi.org/10.1016/j.stemcr.2026.102889)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### FDA assessment of tissue-distribution uncertainty

> “it is unclear how much deramiocel administered IV distributes to the cardiac muscle”

Source: [FDA briefing document (2026)](https://www.fda.gov/media/193839/download)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### HOPE-3: studied age and ambulatory population

> “Ages ≥ 10 who are late or non-ambulatory”

Source: [Capricor Therapeutics AAN presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_98d9213fd51a80017b9973bdbafc2d14/capricor/files/631961/CAPR_AAN_%282026_Presentation%29.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Renal impairment, hepatic impairment, pregnancy, and lactation

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Deramiocel

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Deramiocel on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Dosing and administration in HOPE-3

> “Participants received intravenous Deramiocel at 150 million cells per infusion or placebo every three months for a 12-month period.”

Source: [Capricor Therapeutics HOPE-3 topline results announcement (2025)](https://www.capricor.com/investors/news-events/press-releases/detail/331/capricor-therapeutics-announces-positive-topline-results)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Administration setting

> “in outpatient settings.”

Source: [McDonald et al. (2026)](https://d1io3yog0oux5.cloudfront.net/_fe6d5f8f9bad70880b7ed653911dd676/capricor/files/Lancet_%28HOPE-3%29_Phase_3_publication.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Manufacturing and commercial readiness

> “GMP manufacturing facility in San Diego is operational”
> “Capricor is advancing commercial readiness at a slower pace pending regulatory clarity.”

Source: [Capricor Therapeutics second quarter 2026 results announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/353/capricor-therapeutics-reports-second-quarter-2026-financial)

<a id="topic-2.1.2.11-2"></a>

###### Patient support and access planning

> “Planning is underway across all critical launch functions, including patient support, market access, reimbursement planning, medical affairs and physician education.”

Source: [Capricor Therapeutics first quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926059380/capr-20260512xex99d1.htm)

<a id="topic-2.1.2.11-3"></a>

###### Distribution agreement

> “Capricor appointed Nippon Shinyaku as its exclusive distributor in the United States of Deramiocel for the treatment of DMD.”

Source: [Capricor Therapeutics Form 10-Q (2026)](https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-060382/capr-20260331x10q.htm)

> “The Company seeks rescission of the U.S. Distribution Agreement”

Source: [Capricor Therapeutics Form 8-K (2026)](https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-057221/capr-20260507x8k.htm)

> “Today, the New Jersey state court granted Capricor’s request to pursue its case through arbitration.”

Source: [Capricor Therapeutics legal action announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/343/capricor-therapeutics-takes-legal-action-to-protect-patient)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### HOPE-3: background corticosteroid therapy

> “All patients on background stable corticosteroid therapy”

Source: [Capricor Therapeutics AAN presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_98d9213fd51a80017b9973bdbafc2d14/capricor/files/631961/CAPR_AAN_%282026_Presentation%29.pdf)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Deramiocel on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Deramiocel-specific effects on quality measures

No evidence found.

<a id="topic-2.1.2.13-2"></a>

###### Disease-state evidence: implementation of care considerations

> “males with DMD and Becker muscular dystrophy”
> “Transition planning for education or health care was documented for 31% of eligible males.”

Source: [Andrews et al. (2018)](https://publications.aap.org/pediatrics/article/142/1/e20174006/37450/Implementation-of-Duchenne-Muscular-Dystrophy-Care)

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### HOPE-3: placebo-controlled comparison on background corticosteroids

> “Randomized (1:1), double-blind, placebo-controlled study”
> “All patients on background stable corticosteroid therapy”

Source: [Capricor Therapeutics AAN presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_98d9213fd51a80017b9973bdbafc2d14/capricor/files/631961/CAPR_AAN_%282026_Presentation%29.pdf)

<a id="topic-2.1.2.14-2"></a>

###### Head-to-head comparisons with active DMD therapies

No evidence found.

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Genetic cause

> “Duchenne muscular dystrophy (DMD) is a severe, X-linked disease caused by mutations in the dystrophin gene”

Source: [Li et al. (2025)](https://d1io3yog0oux5.cloudfront.net/_720140307f1b6c7261a7b3c4d8426889/capricor/files/pages/capricor/db/2348/authors/biomedicines-13-02652_%28Capricor%29.pdf)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Duchenne muscular dystrophy

<a id="topic-2.2.1.2.1-1"></a>

###### Australian birth cohort: cumulative incidence

> “The cumulative incidence of disease was 19.7 per 100,000 male live births”

Source: [Kariyawasam et al. (2022)](https://www.nature.com/articles/s41431-022-01138-2)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Duchenne muscular dystrophy

<a id="topic-2.2.1.2.2-1"></a>

###### United States population estimate

> “DMD affects approximately 15,000 individuals in the United States and primarily impacts boys.”

Source: [Capricor Therapeutics HOPE-3 MDA 2026 data announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/339/capricor-therapeutics-announces-late-breaking-hope-3-data)

<a id="topic-2.2.1.2.2-2"></a>

###### Birth prevalence

> “Birth prevalence of DMD has been estimated at 1 in 3,500 (2.9 per 10,000) male births”

Source: [CDC (2009)](https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5840a1.htm)

<a id="topic-2.2.1.2.2-3"></a>

###### Global birth prevalence: pooled estimate

> “the pooled global DMD birth prevalence was 19.8 (95% CI:16.6–23.6) per 100,000 live male births.”

Source: [Crisafulli et al. (2020)](https://link.springer.com/article/10.1186/s13023-020-01430-8)

<a id="topic-2.2.1.2.2-4"></a>

###### Global prevalence among males

> “The pooled global DMD prevalence was 7.1 cases (95% CI: 5.0–10.1) per 100,000 males”

Source: [Crisafulli et al. (2020)](https://link.springer.com/article/10.1186/s13023-020-01430-8)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Life expectancy

> “Median life expectancy with ventilatory support, introduced in most settings in the 1990s, ranged between 21.0 and 39.6 years”

Source: [Landfeldt et al. (2020)](https://link.springer.com/article/10.1007/s10654-020-00613-8)

Additional sources: [Soslow et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37288563/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Dystrophin deficiency and progressive degeneration

> “Dystrophin deficiency leads to progressive muscle degeneration in Duchenne muscular dystrophy (DMD) patients.”

Source: [Rogers et al. (2019)](https://insight.jci.org/articles/view/125754)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Genetic testing before mutation-specific treatment

> “patients with DMD to undergo appropriate genetic testing”

Source: [Muscular Dystrophy Association](https://www.mda.org/disease/duchenne-muscular-dystrophy/medical-management)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Motor symptoms: childhood-onset progressive muscle weakness

> “In boys with Duchenne muscular dystrophy, muscle weakness tends to appear in early childhood and worsen rapidly.”

Source: [MedlinePlus Genetics](https://medlineplus.gov/genetics/condition/duchenne-and-becker-muscular-dystrophy/)

<a id="topic-2.2.1.6-2"></a>

###### Cardiac manifestations: cardiomyopathy

> “Development of cardiomyopathy affects all DMD patients”

Source: [Quinlivan et al. (2021)](https://journals.sagepub.com/doi/10.3233/JND-200609)

<a id="topic-2.2.1.6-3"></a>

###### Cognitive and psychiatric manifestations

> “High rates of intellectual disability (17–27%), learning disabilities (26%), autism spectrum disorder (15%), attention-deficit hyperactivity disorder (32%), and anxiety (27%)”

Source: [DMD Care Considerations Working Group care considerations part 3 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part3.pdf)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Respiratory complications

> “Respiratory complications are a major cause of morbidity and mortality in people with DMD.”

Source: [DMD Care Considerations Working Group care considerations part 2 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part2.pdf)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Duchenne muscular dystrophy

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Humanistic burden: Chilean cross-sectional study

> “Compared with controls, patients reported markedly lower physical functioning (15% vs. 100%) and general health (62% vs. 82%)”

Source: [Avila-Smirnow et al. (2025)](https://www.nature.com/articles/s41598-025-27480-1)

<a id="topic-2.2.1.8.1-2"></a>

###### Health-state utilities

> “Both patient and caregiver utilities trended lower with higher disease severity. Variability in utilities was observed based on instrument, respondent type, and country.”

Source: [Szabo et al. (2020)](https://link.springer.com/article/10.1007/s11136-019-02355-x)

<a id="topic-2.2.1.8.1-3"></a>

###### Health-state utilities: upper-limb function in non-ambulatory DMD

> “Utility values for less severe non-ambulatory health states described by level of upper limb function are novel.”

Source: [Audhya et al. (2023)](https://link.springer.com/article/10.1186/s41687-023-00671-y)

<a id="topic-2.2.1.8.1-4"></a>

###### DMD-QoL and HUI-2 utility estimates

> “DMD-QoL utilities did not vary meaningfully across health states compared with HUI-2 scores, which tended to decline with deteriorating mobility.”

Source: [Bever et al. (2026)](https://link.springer.com/10.1007/s12325-026-03700-6)

<a id="topic-2.2.1.8.1-5"></a>

###### Caregiver anxiety and depression

> “Half of all caregivers (383 of 770) reported being moderately or extremely anxious or depressed”

Source: [Landfeldt et al. (2016)](https://link.springer.com/article/10.1007/s00415-016-8080-9)

Additional sources: [Landfeldt et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29904912/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Health-state utilities, costs, and healthcare resource use in DMD

> “There was heterogeneity between studies and a lack of long-term data in both SLRs.”

Source: [Yip et al. (2026)](https://jheor.org/article/158537-systematic-literature-reviews-of-health-state-utility-values-costs-and-healthcare-resource-use-in-duchenne-muscular-dystrophy)

<a id="topic-2.2.1.8.2-2"></a>

###### Economic burden systematic review

> “the mean per-patient annual direct medical cost of illness (in 2025 international US dollars) was estimated at between $2620 and $209,980”

Source: [Landfeldt et al. (2026)](https://link.springer.com/article/10.1007/s40273-026-01610-7)

<a id="topic-2.2.1.8.2-3"></a>

###### United States medical costs: Medicaid and commercial insurance

> “(in 2018 USD)”
> “median (IQR) monthly costs were similar at $1,735 ($367-$5,281) for the Medicaid DMD cohort vs $1,883 ($657-$6,796) for the commercial DMD cohort.”

Source: [Klimchak et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391028/)

<a id="topic-2.2.1.8.2-4"></a>

###### Multinational cost-of-illness study

> “Mean per-patient annual direct cost of illness was estimated at between $23,920 and $54,270 (2012 international dollars)”

Source: [Landfeldt et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4141999/)

<a id="topic-2.2.1.8.2-5"></a>

###### United States healthcare costs: DMD versus matched non-MD controls

> “mean unadjusted total healthcare costs (US$103,826.05 ± 309,335.71) per patient per year compared with patients with non-MD (US$3225.30 ± 13,865.14; p < 0.0001)”

Source: [Scavina et al. (2026)](https://link.springer.com/article/10.1007/s41669-025-00612-z)

Additional sources: [PharmacoEconomics–Open (2026)](https://link.springer.com/article/10.1007/s41669-026-00646-x)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Duchenne muscular dystrophy on Families

<a id="topic-2.2.1.8.3-1"></a>

###### United States household costs

> “Average (SD) household costs over the past 5 years were $78,303 ($78,411) for home/vehicle expenses and $14,071 ($27,427) for medical equipment.”

Source: [Innis et al. (2025)](https://link.springer.com/article/10.1186/s13023-025-03794-1)

<a id="topic-2.2.1.8.3-2"></a>

###### Caregiver productivity: Europe, Japan, and the United States

> “Mean caregiver absenteeism, presenteeism and overall work impairment were 9.7%, 37.8% and 42.4%, respectively”

Source: [Strober et al. (2026)](https://link.springer.com/article/10.1186/s12883-025-04531-8)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Disease-level newborn-screening model

> “Newborn screening via CK testing and genetic testing would cost an estimated $392,061 and $447,170 per life year gained, respectively.”

Source: [Smith et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-5/impact-of-newborn-screening-for-duchenne-muscular-dystrophy-a-model-based-analysis)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Corticosteroids

<a id="topic-2.2.2.1.1-1"></a>

###### Glucocorticoids after loss of ambulation

> “treatment with glucocorticoids remain the mainstays of DMD treatment and should continue after loss of ambulation.”

Source: [DMD Care Considerations Working Group care considerations part 1 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part1.pdf)

<a id="topic-2.2.2.1.1-2"></a>

###### Current corticosteroid options

> “prednisone, deflazacort, and vamoralone”

Source: [Muscular Dystrophy Association](https://www.mda.org/disease/duchenne-muscular-dystrophy/medical-management)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Gene Replacement Therapy

<a id="topic-2.2.2.1.2-1"></a>

###### Delandistrogene moxeparvovec: revised eligible population

> “ambulatory patients with DMD who are 4 years of age and older with a confirmed mutation in the DMD gene”

Source: [FDA (2025)](https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal)

<a id="topic-2.2.2.1.2-2"></a>

###### Other treatment options: delandistrogene moxeparvovec

> “serious liver injury and acute liver failure, including fatal outcomes”
> “Removal of the indication for non-ambulatory patients with DMD”

Source: [FDA (2025)](https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Exon-skipping Antisense Oligonucleotides

<a id="topic-2.2.2.1.3-1"></a>

###### Mutation-specific exon-skipping options

| Drug | Required exon-skipping amenability |
| --- | --- |
| Casimersen | “skipping exon 45.” |
| Viltolarsen | “skipping exon 53.” |
| Golodirsen | “skipping exon 53.” |
| Eteplirsen | “skipping exon 51.” |

Source: [Muscular Dystrophy Association](https://www.mda.org/disease/duchenne-muscular-dystrophy/medical-management)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Histone Deacetylase Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### Givinostat: therapeutic class and treated age range

> “histone deacetylase (HDAC) inhibitor”
> “patients six years of age and older.”

Source: [FDA (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy)

<a id="topic-2.2.2.1.4-2"></a>

###### Other treatment options: givinostat

> “Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD.”

Source: [FDA (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Physical and Occupational Therapy

<a id="topic-2.2.2.1.5-1"></a>

###### Rehabilitation: prevention of contracture and deformity

> “Daily preventive home stretching 4–6 times per week;”

Source: [DMD Care Considerations Working Group care considerations part 1 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part1.pdf)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Cardioprotective Therapies

<a id="topic-2.2.2.1.6-1"></a>

###### Cardiac treatment

> “Initiate angiotensin-converting enzyme inhibitors or angiotensin receptor blockers by age 10”

Source: [DMD Care Considerations Working Group care considerations part 2 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part2.pdf)

Additional sources: [Bourke et al. (2022)](https://openheart.bmj.com/content/9/2/e001977)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Respiratory Support

<a id="topic-2.2.2.1.7-1"></a>

###### Assisted lung inflation, cough, and ventilation

> “lung volume recruitment, assisted coughing, nocturnally assisted ventilation”

Source: [DMD Care Considerations Working Group care considerations part 2 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part2.pdf)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Bone Health Therapies

<a id="topic-2.2.2.1.8-1"></a>

###### Fracture-related bone protection: treatment options

> “anti-resorptive therapies with bisphosphonate (intravenous or oral)”

Source: [Quinlivan et al. (2021)](https://journals.sagepub.com/doi/10.3233/JND-200609)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Nutritional Support

<a id="topic-2.2.2.1.9-1"></a>

###### Recurrent weight loss

> “Recurrent weight loss requires input from a dietitian”

Source: [Quinlivan et al. (2021)](https://journals.sagepub.com/doi/10.3233/JND-200609)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Psychosocial Support

<a id="topic-2.2.2.1.10-1"></a>

###### Psychosocial care

> “The neuromuscular care team should include a mental health professional”

Source: [DMD Care Considerations Working Group care considerations part 3 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part3.pdf)

<a id="heading-2.2.2.1.11"></a>

###### 2.2.2.1.11 Limitations of Current Therapies

<a id="topic-2.2.2.1.11-1"></a>

###### Summary

Current treatment combines disease-directed therapy with rehabilitation and organ-specific supportive care. Corticosteroid adverse effects include weight gain, behavioural changes, growth suppression, bone loss, and cataracts. Exon-skipping options require mutations amenable to skipping a specified exon. The revised delandistrogene moxeparvovec indication is limited to ambulatory patients aged four years or older with a confirmed DMD mutation, and FDA identifies risks of serious liver injury and acute liver failure, including fatal outcomes. These eligibility restrictions and adverse effects limit the applicability of available therapies across the DMD population.

Source: [DMD Care Considerations Working Group care considerations part 1 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part1.pdf); [DMD Care Considerations Working Group care considerations part 2 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part2.pdf); [DMD Care Considerations Working Group care considerations part 3 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part3.pdf); [Muscular Dystrophy Association](https://www.mda.org/disease/duchenne-muscular-dystrophy/medical-management); [FDA (2025)](https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal)

<a id="topic-2.2.2.1.11-2"></a>

###### Corticosteroid treatment limitations

> “Long-term side effects include weight gain, behavioral changes, growth suppression, bone loss, and cataracts.”

Source: [Muscular Dystrophy Association](https://www.mda.org/disease/duchenne-muscular-dystrophy/medical-management)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

Deramiocel has been studied as an intravenous treatment administered every three months in outpatient settings, with HOPE-3 participants receiving stable background corticosteroid therapy. The studied population was aged at least ten years and late ambulatory or non-ambulatory. The sponsor’s refined proposed indication focuses on upper limb function. The evidence therefore concerns treatment added to existing care in this trial population; it does not establish an approved treatment position or support replacing corticosteroids or multidisciplinary care.

Source: [Capricor Therapeutics HOPE-3 topline results announcement (2025)](https://www.capricor.com/investors/news-events/press-releases/detail/331/capricor-therapeutics-announces-positive-topline-results); [McDonald et al. (2026)](https://d1io3yog0oux5.cloudfront.net/_fe6d5f8f9bad70880b7ed653911dd676/capricor/files/Lancet_%28HOPE-3%29_Phase_3_publication.pdf); [Capricor Therapeutics AAN presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_98d9213fd51a80017b9973bdbafc2d14/capricor/files/631961/CAPR_AAN_%282026_Presentation%29.pdf); [Capricor Therapeutics PDUFA date extension announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/354/capricor-therapeutics-announces-extension-of-pdufa-target); [Capricor Therapeutics Form 10-K (2026)](https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-029580/capr-20251231x10k.htm)

Additional sources: [Tang and Yokota (2024)](https://pubmed.ncbi.nlm.nih.gov/38291016/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### HOPE-3: cardiomyopathy subgroup analysis

| Measure | Reported value |
| --- | --- |
| LVEF difference at 12 months, percentage points | “3.3” |
| Ranked-comparison p value | “0.017” |
| Evaluable participants | “64” |

Source: [Capricor Therapeutics MDA presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_72a8420b8089fb55954d5909808b3da2/capricor/files/631961/MDA_2026_CAPR_3.11.26_late-breaker.pdf)

> “Prespecified endpoint not TYPE-I error controlled”

Source: [Capricor Therapeutics MDA presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_72a8420b8089fb55954d5909808b3da2/capricor/files/631961/MDA_2026_CAPR_3.11.26_late-breaker.pdf)

<a id="topic-2.2.2.3-2"></a>

###### FDA assessment of the cardiomyopathy definition

> “FDA does not agree with the Applicant’s definition of cardiomyopathy”

Source: [FDA briefing document (2026)](https://www.fda.gov/media/193839/download)

<a id="topic-2.2.2.3-3"></a>

###### Formal treatment-by-subgroup interaction analysis

No evidence found.

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Cardiac monitoring

> “Conduct cardiac assessment at least annually”

Source: [DMD Care Considerations Working Group care considerations part 2 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part2.pdf)

<a id="topic-2.2.2.4-2"></a>

###### Adult DMD care and cardiac monitoring

> “All patients should have annual cardiologist follow up with assessment of cardiac function by echo or cMRI.”

Source: [Quinlivan et al. (2021)](https://journals.sagepub.com/doi/10.3233/JND-200609)

<a id="topic-2.2.2.4-3"></a>

###### Caregiver support

> “Assist with arranging respite care for caregivers”

Source: [DMD Care Considerations Working Group care considerations part 3 (2018)](https://www.parentprojectmd.org/wp-content/uploads/2018/06/Duchenne_CareConsiderations_2018_Part3.pdf)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Proposed functional target

> “a refined proposed indication focused on upper limb function”

Source: [Capricor Therapeutics PDUFA date extension announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/354/capricor-therapeutics-announces-extension-of-pdufa-target)

## Related pages
- [Deramiocel (CAP-1002): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Terms and abbreviations](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/terms-and-abbreviations.md)
- [Deramiocel (CAP-1002): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/executive-summary.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Clinical evidence](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/clinical-evidence.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Economic information and modeling report](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/economics) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/economics.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: References](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/references) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/references.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: prevalence by geography](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/prevalence) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/prevalence.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/cost-effectiveness-analyses.md)
